Director, Global Value and Health Economics

Jazz Pharmaceuticals

. Lead global and US payer evidence strategy across marketed assets in Jazz’s neurology portfolio .

Posted 11/5/2026full-timeRemote • United States, United KingdomLead💰 $212,000 - $318,000 per yearWebsite

Core Competencies

Role fit

Core Competencies

Use this summary to align your resume positioning with the role.

Demonstrates expertise in Health Economics and Outcomes Research (HEOR) with a focus on evidence generation strategies for marketed pharmaceutical products. Proficient in developing economic models and conducting real-world studies to support value defense and regulatory submissions.

Highest-signal resume keywords

Health Economics ExpertiseReal-World Evidence GenerationEconomic Model DevelopmentCross-Functional CollaborationNeurology Portfolio Experience

ATS Keywords

Tailor your resume

Applicant Tracking System Keywords

Tip: use these terms in your resume and cover letter to boost ATS matches.

Hard Skills

Health EconomicsOutcomes ResearchComparative Effectiveness StudiesEconomic ModelingPost-Marketing StrategiesReal-World Data AnalysisBudget Impact ModelingPhase 3b/4 Trials OptimizationRegulatory SubmissionsEvidence Generation Plans

Soft Skills

Exceptional Communication SkillsInfluencing Cross-Functional TeamsMentorship and Technical Guidance

Tools & Technologies

Healthcare DatabasesStatistical SoftwareEconomic Modeling Software

Industry Keywords

Managed Care LandscapeHealth Technology Assessment (HTA)Rare DiseasesPharmaceutical IndustryBiopharmaceuticals

About the role

Key responsibilities & impact

Lead global and US payer evidence strategy across marketed assets in Jazz’s neurology portfolio
Maximize brand potential, defend value, secure expanded access, and drive evidence generation across the post-launch lifecycle
Translate commercial, access, and policy priorities into evidence generation plans and deliverables
Lead HEOR evidence strategies supporting supplemental regulatory filings, new indications, line extensions, expanded subpopulations, and novel formulations/devices
Optimize Phase 3b/4 trials, pragmatic studies, and expanded access programs with payer-relevant endpoints, PROs, and HRQoL measures
Partner with Market Access on indication sequencing and access strategy
Lead rare disease registries, natural history extensions, and post-authorization safety/efficacy studies
Design comparative effectiveness, adherence, burden-of-illness, and real-world data studies to defend product value
Co-create HTA re-assessment strategies and deliver updated NMAs, ITCs, economic models, and evidence packages
Direct updates of Global Value Dossiers, systematic literature reviews, and meta-analyses
Serve as designated US HEOR expert for assigned inline products
Lead AMCP dossiers, unbranded value summaries, and state Medicaid submission dossiers
Develop and train teams on interactive economic models and reactive scientific presentations
Ensure US HEOR deliverables comply with FDAMA Section 114, the 21st Century Cures Act, and FDA HCEI guidance
Evaluate outcomes-based risk-sharing agreements and establish real-world endpoint tracking frameworks
Monitor US health policy and prepare evidence plans and materials for ICER and other value assessment bodies
Build and adapt cost-effectiveness, cost-utility, budget impact, cost-offset, Markov, partitioned survival, microsimulation, and dynamic population models
Govern Integrated Evidence Generation Plans for inline assets
Partner with Market Access, Medical Affairs, Commercial Brand, Regulatory Affairs, Biostatistics, and RWE teams
Lead publications and conference presentations at ISPOR, AMCP, and disease-specific congresses
Manage vendors, consultancies, academic partners, CROs, budgets, quality, timelines, and compliance
Provide mentorship and technical guidance to associate directors, managers, and fellows

Requirements

What you’ll need

Master’s degree (MSc, MS, MPH) or PhD in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field
Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm
Extensive experience designing and executing post-marketing HEOR strategies, real-world comparative effectiveness studies, and evidence roadmaps supporting label expansions, line extensions, and value defense
Comprehensive working knowledge of the US managed care landscape and global HTA environments
Proven technical expertise building, adapting, and validating economic models, including Markov, partitioned survival, microsimulation, and dynamic budget impact models
Proven track record collaborating with US Market Access, Pricing/Contracting, and Payer Field Teams
Demonstrated understanding of rare disease and orphan product post-launch evidence challenges
Working knowledge of major US and global healthcare databases and advanced epidemiological methods
Ability to balance evidence strategy with hands-on execution of complex technical deliverables
Exceptional verbal, written, and presentation skills
Demonstrated ability to influence cross-functional matrix teams and defend methodologies before payers, HTA authorities, and scientific reviewers
Experience with neurology assets preferred
Demonstrated track record leading HEOR strategy and executing evidence deliverables for marketed pharmaceutical products
Launch lead for at least 2 assets as US HEOR lead, or country-level HTA lead
Experience conducting post-marketing RWE, patient registry studies, and economic evaluations in rare diseases, specialized medicine, or complex chronic conditions
Substantial experience collaborating with regional HEOR teams to deliver global HTA re-assessment packages
Strong peer-reviewed publication record in health economics and outcomes research

Benefits

Comp & perks

Discretionary annual cash bonus or incentive compensation
Discretionary equity grants through the Long Term Equity Incentive Plan
Medical insurance
Dental insurance
Vision insurance
401k retirement savings plan
Flexible paid vacation